HC Wainwright Increases NovoCure (NASDAQ:NVCR) Price Target to $52.00

NovoCure (NASDAQ:NVCR) had its target price hoisted by equities researchers at HC Wainwright from $46.00 to $52.00 in a research report issued to clients and investors on Thursday, MarketBeat.com reports. The firm currently has a “buy” rating on the medical equipment provider’s stock. HC Wainwright’s price target suggests a potential upside of 194.62% from the company’s previous close. HC Wainwright also issued estimates for NovoCure’s FY2029 earnings at $1.90 EPS.

A number of other analysts also recently weighed in on the stock. Evercore reaffirmed an “outperform” rating on shares of NovoCure in a research report on Friday, May 1st. Zacks Research cut shares of NovoCure from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. JPMorgan Chase & Co. began coverage on NovoCure in a research report on Monday, July 13th. They issued a “neutral” rating and a $17.00 price target on the stock. Weiss Ratings raised NovoCure from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 1st. Finally, Wells Fargo & Company lifted their price objective on NovoCure from $13.50 to $17.00 and gave the company an “equal weight” rating in a research note on Monday, May 4th. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, NovoCure has a consensus rating of “Hold” and an average target price of $21.20.

NovoCure Trading Down 11.7%

NVCR opened at $17.65 on Thursday. The company has a quick ratio of 2.70, a current ratio of 2.90 and a debt-to-equity ratio of 0.71. NovoCure has a 52 week low of $9.82 and a 52 week high of $21.45. The stock has a market cap of $2.04 billion, a PE ratio of -13.58 and a beta of 0.94. The business has a 50 day moving average of $16.64 and a 200-day moving average of $14.14.

NovoCure (NASDAQ:NVCR) last issued its quarterly earnings results on Thursday, July 23rd. The medical equipment provider reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.20. The company had revenue of $183.58 million for the quarter, compared to analysts’ expectations of $172.44 million. NovoCure had a negative return on equity of 44.02% and a negative net margin of 21.25%.The firm’s revenue for the quarter was up 15.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.36) earnings per share. Equities research analysts predict that NovoCure will post -1.52 earnings per share for the current fiscal year.

Insider Buying and Selling at NovoCure

In other news, Director W Anthony Vernon sold 2,945 shares of NovoCure stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $15.77, for a total value of $46,442.65. Following the completion of the sale, the director directly owned 197,657 shares in the company, valued at $3,117,050.89. The trade was a 1.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Timothy J. Scannell sold 2,945 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $15.77, for a total transaction of $46,442.65. Following the transaction, the director directly owned 14,288 shares of the company’s stock, valued at $225,321.76. The trade was a 17.09% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 51,943 shares of company stock worth $893,171. 5.52% of the stock is owned by company insiders.

Institutional Investors Weigh In On NovoCure

Hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. grew its position in NovoCure by 104.2% in the third quarter. JPMorgan Chase & Co. now owns 282,184 shares of the medical equipment provider’s stock worth $3,646,000 after acquiring an additional 144,024 shares in the last quarter. Tudor Investment Corp ET AL boosted its stake in NovoCure by 140.6% during the third quarter. Tudor Investment Corp ET AL now owns 606,070 shares of the medical equipment provider’s stock worth $7,830,000 after buying an additional 354,216 shares during the period. SG Americas Securities LLC boosted its stake in NovoCure by 905.6% during the fourth quarter. SG Americas Securities LLC now owns 278,806 shares of the medical equipment provider’s stock worth $3,605,000 after buying an additional 251,082 shares during the period. Vanguard Group Inc. increased its position in NovoCure by 4.8% during the fourth quarter. Vanguard Group Inc. now owns 10,958,209 shares of the medical equipment provider’s stock valued at $141,690,000 after acquiring an additional 502,368 shares during the last quarter. Finally, Eversept Partners LP bought a new position in NovoCure during the fourth quarter valued at $1,564,000. Hedge funds and other institutional investors own 84.61% of the company’s stock.

NovoCure News Roundup

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: NovoCure reported Q2 EPS of -$0.13, beating the consensus loss estimate of -$0.33, while revenue came in at $183.6 million versus expectations of $172.4 million. Revenue also rose 15.6% year over year, signaling improving business momentum.
• Positive Sentiment: The company raised its FY2026 revenue guidance to $710 million-$725 million, above the market’s prior expectation of about $704 million, which suggests management sees continued demand strength.
• Positive Sentiment: HC Wainwright increased its price target on NovoCure to $52 from $46 and maintained a Buy rating, reinforcing optimism around the company’s longer-term earnings potential. Article Title
• Neutral Sentiment: Wedbush also raised its price target to $20 from $18, but kept a Neutral rating, indicating improved expectations without a strong bullish call. Article Title
• Neutral Sentiment: Shares also got a lift from optimism around the company’s brain therapy pipeline and possible FDA-related catalysts, which helped push the stock to new highs as investors priced in further upside. Article Title
• Negative Sentiment: HC Wainwright trimmed its FY2029 EPS estimate slightly to $1.90 from $1.95, a small caution on the company’s very long-term earnings outlook.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.